Semantic Coherence: Sanofi – Signal Evidence & AI Readability

[IMG: Banafsheh Mehrazma, Vaccines Technologist at Sanofi]
Banafsheh Mehrazma, Technologist, Vaccines, Toronto Campus, CanadaBanafsheh Mehrazma, Technologist, Vaccines, Toronto Campus, Canada
[H1] First Quarter 2026
First quarter 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.Learn more
[H2] Our Latest Articles
Read our latest articles
[IMG: Rich, who lives with severe Hemophilia A, enjoying time outdoors.]
Your HealthApril 27, 2026
[H3] Global Hemophilia Survey Amplifies Patient and Caregiver Voices
Read the article
[IMG: The F protein of the Respiratory Syncytial Virus (RSV), with a molecular clamp (purple) and key epitopes exposed (yellow).]
Our ScienceApril 20, 2026
[H3] Shape Matters: Inside Molecular Clamp Vaccines
Read the article
[IMG: Mark, who lives with severe hemophilia A, with his family.]
Your HealthApril 17, 2026
[H3] It’s Time to Look Beyond the Bleed
Read the article
[IMG: Two women in black wetsuits standing on a beach with a surfboard, ready for surfing]
[H2] The Power of Chasing A Dream
Every day, we chase the miracles of science to improve people’s lives. We apply our deep understanding of the immune system to develop breakthrough innovations in medicines and vaccines so you can focus on what matters most, chasing your dreams. If you’re chasing your dreams, remember... you’re not alone. We’re right beside you

[H2] People Stories
[H4] We’re proud to spotlight those who inspire us to keep going further in the work we do.
[IMG: A woman wearing a black wetsuit holds a surfboard under blue skies and sunshine while looking out to the horizon with a hopeful and determined expression.​]
[H3] Céline, living with secondary progressive multiple sclerosis
France
Read more
[IMG: A man wearing glasses and a blue jacket operates a video camera and looks focused while filming, his hand is outstretched in front of him as he gestures. ​]
[H3] Xavier, living with autoimmune type 1 diabetes
US
Read more
[IMG: A woman in a white Sanofi lab coat and company badge outside of a building, moving forward while confidently and positively looking ahead. Several people are running alongside her in the background.​]
[H3] Wei, Sanofi
China
Read moreSee all stories
[H2] We are an R&D driven, AI-powered biopharmaceutical company committed to improving people’s lives and delivering compelling growth.
[H2] About Us
[H3] Who We Are
We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.
Read more
[H3] Our Science
We turn the impossible into possible.
Read more
[H3] Your Health
We chase the miracles of science to improve people’s lives.
Read more
[IMG: An straight down drone view of Garrarus beach, Waterford Ireland, with sea green waters, coarse sandy beach, and a rocky coast]
[H3] Sustainability
We are at the forefront of addressing some of the world's most critical challenges, striving to create a healthier, more resilient future.
Read more
[H2] Our Pipeline
[H3] 5
Therapeutic areas
[H3] 77
Compounds in clinical development
[H3] 21
Clinical trials in phase 3
Explore our pipeline
[H2] Pursue Progress. Discover Extraordinary.
Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.
Explore Career Opportunities
[H2] Our Latest Press Releases
April 29, 2026Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of SanofiRead the Press ReleaseApril 24, 2026Press Release: Sanofi successfully prices 2.3 billion of bond issueRead the Press ReleaseApril 24, 2026Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapsesRead the Press ReleaseApril 23, 2026Press Release: Q1 2026: double-digit sales and business EPS growthRead the Press ReleaseSee all press releases

[H1] Press Releases
Filter per yearFilter per categoryApril 29, 2026Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of SanofiRead the Press ReleaseApril 24, 2026Press Release: Sanofi successfully prices 2.3 billion of bond issueRead the Press ReleaseApril 24, 2026Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapsesRead the Press ReleaseApril 23, 2026Press Release: Q1 2026: double-digit sales and business EPS growthRead the Press ReleaseApril 22, 2026Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticariaRead the Press ReleaseApril 22, 2026Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young childrenRead the Press ReleaseApril 22, 2026Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the USRead the Press ReleaseApril 18, 2026Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head studyRead the Press ReleaseApril 13, 2026Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticariaRead the Press ReleaseApril 7, 2026Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP Read the Press ReleaseMarch 31, 2026Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host diseaseRead the Press ReleaseMarch 28, 2026Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionRead the Press ReleaseMarch 27, 2026Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myelomaRead the Press ReleaseMarch 24, 2026Press release: Availability of the Q1 2026 aide-mémoireRead the Press ReleaseMarch 24, 2026Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidRead the Press ReleaseMarch 18, 2026Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher diseaseRead the Press ReleaseMarch 5, 2026Press Release:  Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent directorRead the Press ReleaseMarch 4, 2026Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial ReportRead the Press ReleaseMarch 2, 2026Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related diseaseRead the Press ReleaseFebruary 27, 2026Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatmentRead the Press Release
[H2] Press Statements
See more

[H1] Our Pipeline
Updated on April 23, 2026.Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 77 clinical-stage projects, 34 of which are in phase 3 or have been submitted to regulatory authorities for approval. Some of these are new molecular entities while others are existing products with potential new indications, or different formulations. All of them are made possible by people who volunteer to participate in a clinical trial.Phase 115Phase 228Phase 328Registration6Changes that occurred in our R&D pipeline are detailed in our quarterly earnings press release, issued on April 23, 2026.
[H2] Search for a Specific Clinical-Stage Project
All therapeutic areasAll phasesAll expected timeline77 project(s) of 77Clear FiltersTherapeutic AreaPhaseNameDescriptionIndicationTherapeutic AreaImmunology123RNameSAR446422Phase123RDescriptionCD28xOX40 bispecific AbIndicationInflammatory indicationInflammatory indicationTherapeutic AreaImmunology123RNameSAR446959Phase123RDescriptionMMP13xADAMTS5xCAP Nanobody® VHHIndicationKnee osteoarthritis Knee osteoarthritis Therapeutic AreaImmunology123RNameSAR448501Phase123RDescriptionCD20 bispecific mAbIndicationInflammatory indicationInflammatory indicationTherapeutic AreaImmunology123RNamebalinatunfibPhase123RDescriptionOral TNFR1 signaling inhibitorIndicationUlcerative colitisUlcerative colitisTherapeutic AreaImmunology123RNamebalinatunfibPhase123RDescriptionOral TNFR1 signaling inhibitorIndicationCrohn’s diseaseCrohn’s diseaseTherapeutic AreaImmunology123RNamebrivekimigPhase123RDescriptionTNFaxOX40L Nanobody® VHHIndicationType 1 diabetes, stage 3Type 1 diabetes, stage 3Therapeutic AreaImmunology123RNamebrivekimigPhase123RDescriptionTNFaxOX40L Nanobody® VHHIndicationCrohn’s diseaseCrohn’s diseaseTherapeutic AreaImmunology123RNamebrivekimigPhase123RDescriptionTNFaxOX40L Nanobody® VHHIndicationUlcerative colitisUlcerative colitisTherapeutic AreaImmunology123RNamebrivekimigPhase123RDescriptionTNFaxOX40L Nanobody® VHHIndicationHidradenitis suppurativaHidradenitis suppurativaTherapeutic AreaImmunology123RNamefrexalimabPhase123RDescriptionCD40L mAbIndicationType 1 diabetesType 1 diabetesTherapeutic AreaImmunology123RNameitepekimabPhase123RDescriptionIL33 mAbIndicationChronic rhinosinusitis without nasal polypsChronic rhinosinusitis without nasal polypsTherapeutic AreaImmunology123RNamelunsekimigPhase123RDescriptionIL13xTSLP Nanobody® VHHIndicationAsthma, high-riskAsthma, high-riskTherapeutic AreaImmunology123RNamelunsekimigPhase123RDescriptionIL13xTSLP Nanobody® VHHIndicationChronic rhinosinusitis with nasal polypsChronic rhinosinusitis with nasal polypsTherapeutic AreaImmunology123RNamelunsekimigPhase123RDescriptionIL13xTSLP Nanobody® VHHIndicationAsthmaAsthmaTherapeutic AreaImmunology123RNameriliprubartPhase123RDescriptionC1s mAbIndicationAntibody-mediated rejectionAntibody-mediated rejectionTherapeutic AreaImmunology123RNamerilzabrutinibPhase123RDescriptionBTK inhibitorIndicationChronic spontaneous urticariaChronic spontaneous urticariaTherapeutic AreaImmunology123RNamerilzabrutinibPhase123RDescriptionBTK inhibitorIndicationAsthmaAsthmaTherapeutic AreaImmunology123RNamerovadicitinibPhase123RDescriptionJAK/ROCK inhibitorNewIndicationChronic graft-versus-host disease, 2LNewChronic graft-versus-host disease, 2LNewTherapeutic AreaImmunology123RNameSAR444336Phase123RDescriptionNon-beta IL2 Synthorin™IndicationMicroscopic colitisMicroscopic colitisTherapeutic AreaImmunology123RNameSAR445399Phase123RDescriptionIL1R3 mAb IndicationHidradenitis suppurativaHidradenitis suppurativaTherapeutic AreaImmunology123RNameSAR449028Phase123RDescriptionWild-type KIT inhibitorIndicationChronic induced/spontaneous urticariaChronic induced/spontaneous urticariaTherapeutic AreaImmunology123RNameamlitelimabPhase123RDescriptionOX40L mAbIndicationAtopic dermatitisAtopic dermatitisTherapeutic AreaImmunology123RNameDupixentPhase123RDescriptionIL4R mAbIndicationLichen simplex chronicusLichen simplex chronicusTherapeutic AreaImmunology123RNameDupixentPhase123RDescriptionIL4R mAbIndicationChronic pruritis of unknown originChronic pruritis of unknown originTherapeutic AreaImmunology123RNameduvakitugPhase123RDescriptionTL1A mAbIndicationCrohn's diseaseCrohn's diseaseTherapeutic AreaImmunology123RNameduvakitugPhase123RDescriptionTL1A mAbIndicationUlcerative colitisUlcerative colitisTherapeutic AreaImmunology123RNamefrexalimabPhase123RDescriptionCD40L mAbNew phaseIndicationKidney transplant rejectionNew phaseKidney transplant rejectionNew phaseTherapeutic AreaImmunology123RNameitepekimabPhase123RDescriptionIL33 mAbIndicationChronic rhinosinusitis with nasal polypsChronic rhinosinusitis with nasal polypsTherapeutic AreaImmunology123RNameitepekimabPhase123RDescriptionIL33 mAbIndicationChronic obstructive pulmonary diseaseChronic obstructive pulmonary diseaseTherapeutic AreaImmunology123RNamelunsekimigPhase123RDescriptionIL13xTSLP Nanobody® VHHIndicationChronic obstructive pulmonary diseaseChronic obstructive pulmonary diseaseTherapeutic AreaImmunology123RNameRezurockPhase123RDescriptionROCK2 inhibitorIndicationChronic lung allograft dysfunction Chronic lung allograft dysfunction Therapeutic AreaImmunology123RNameDupixentPhase123RDescriptionIL4R mAbIndicationBullous pemphigoid (EU)Bullous pemphigoid (EU)Therapeutic AreaImmunology123RNameTzieldPhase123RDescriptionCD3 mAbIndicationType 1 diabetes, stage 3 (US)Type 1 diabetes, stage 3 (US)Therapeutic AreaNeurology123RNameSAR446597Phase123RDescriptionBbxC1s AAV gene therapyIndicationGeographic atrophy in dry age-related macular degenerationGeographic atrophy in dry age-related macular degenerationTherapeutic AreaNeurology123RNameSAR448851Phase123RDescriptionTREM2 agonistIndicationAlzheimer’s diseaseAlzheimer’s diseaseTherapeutic AreaNeurology123RNameSAR402663Phase123RDescriptionsFLT01 AAV gene therapyIndicationWet age-related macular degenerationWet age-related macular degenerationTherapeutic AreaNeurology123RNamefrexalimabPhase123RDescriptionCD40L mAbIndicationNon-relapsing secondary progressive MSNon-relapsing secondary progressive MSTherapeutic AreaNeurology123RNamefrexalimabPhase123RDescriptionCD40L mAbIndicationRelapsing multiple sclerosisRelapsing multiple sclerosisTherapeutic AreaNeurology123RNameriliprubartPhase123RDescriptionC1s mAbIndicationIVIg-treated CIDPIVIg-treated CIDPTherapeutic AreaNeurology123RNameriliprubartPhase123RDescriptionC1s mAbIndicationSOC-refractory CIDPSOC-refractory CIDPTherapeutic AreaNeurology123RNametolebrutinibPhase123RDescriptionBTK inhibitorIndicationSecondary progressive MS (US, EU)Secondary progressive MS (US, EU)Therapeutic AreaOncology123RNameSAR445953Phase123RDescriptionCEACAM5-Topo1 ADCIndicationColorectal cancerColorectal cancerTherapeutic AreaOncology123RNameSAR446523Phase123RDescriptionGPRC5D mAbIndicationRelapsed/refractory multiple myelomaRelapsed/refractory multiple myelomaTherapeutic AreaOncology123RNameSAR445877Phase123RDescriptionPD1xIL15 fusion proteinIndicationSolid tumorsSolid tumorsTherapeutic AreaOncology123RNameSarclisaPhase123RDescriptionCD38 mAbIndicationRelapsed/refractory multiple myeloma in combinationRelapsed/refractory multiple myeloma in combinationTherapeutic AreaOncology123RNameSarclisaPhase123RDescriptionCD38 mAbIndicationNDMM, TE (IsKia)NDMM, TE (IsKia)Therapeutic AreaOncology123RNameSarclisaPhase123RDescriptionCD38 mAbIndicationSmoldering multiple myeloma (ITHACA)Smoldering multiple myeloma (ITHACA)Therapeutic AreaOncology123RNameSarclisaPhase123RDescriptionCD38 mAbIndicationNDMM, TE (HD7)NDMM, TE (HD7)Therapeutic AreaOncology123RNameSarclisaPhase123RDescriptionCD38 mAb subcutaneousIndicationMultiple myelomaMultiple myelomaTherapeutic AreaRare Diseases123RNameSAR446268Phase123RDescriptionDMPK AAV gene therapyIndicationMyotonic dystrophy type 1Myotonic dystrophy type 1Therapeutic AreaRare Diseases123RNameefdoralprin alfaPhase123RDescriptionAAT fusion proteinIndicationAlpha-1 antitrypsin deficiency emphysemaAlpha-1 antitrypsin deficiency emphysemaTherapeutic AreaRare Diseases123RNamefrexalimab, rilzabrutinib, brivekimigPhase123RDescriptionCD40L mAb, BTK inhibitor, TNFaxOX40L Nanobody® VHHIndicationFocal segmental glomerulosclerosis / minimal change diseaseFocal segmental glomerulosclerosis / minimal change diseaseTherapeutic AreaRare Diseases123RNameWayrilzPhase123RDescriptionBTK inhibitorIndicationGraves' diseaseGraves' diseaseTherapeutic AreaRare Diseases123RNameelenestinibPhase123RDescriptionD816V-mutated KIT inhibitorIndicationIndolent/smoldering systemic mastocytosisIndolent/smoldering systemic mastocytosisTherapeutic AreaRare Diseases123RNamefitusiranPhase123RDescriptionRNAi targeting antithrombinIndicationHemophilia A and B (EU, JP)Hemophilia A and B (EU, JP)Therapeutic AreaRare Diseases123RNameNexviazymePhase123RDescriptionEnzyme replacement therapyIndicationInfantile-onset Pompe diseaseInfantile-onset Pompe diseaseTherapeutic AreaRare Diseases123RNamevenglustatPhase123RDescriptionOral GCS inhibitorIndicationFabry diseaseFabry diseaseTherapeutic AreaRare Diseases123RNamevenglustatPhase123RDescriptionOral GCS inhibitorIndicationGaucher disease type 3Gaucher disease type 3Therapeutic AreaRare Diseases123RNameWayrilzPhase123RDescriptionBTK inhibitorIndicationIgG4-related diseaseIgG4-related diseaseTherapeutic AreaRare Diseases123RNameWayrilzPhase123RDescriptionBTK inhibitorIndicationSickle cell diseaseSickle cell diseaseTherapeutic AreaRare Diseases123RNameWayrilzPhase123RDescriptionBTK inhibitorIndicationWarm autoimmune hemolytic anemia Warm autoimmune hemolytic anemia Therapeutic AreaRare Diseases123RNameWayrilzPhase123RDescriptionBTK inhibitorIndicationImmune thrombocytopenia (JP)Immune thrombocytopenia (JP)Therapeutic AreaVaccines123RNameSP0269Phase123RDescriptionmRNA vaccineIndicationChlamydiaChlamydiaTherapeutic AreaVaccines123RNameSP0287Phase123RDescriptionFlublok+NuvaxovidIndicationFlu+COVID-19Flu+COVID-19Therapeutic AreaVaccines123RNameSP0287Phase123RDescriptionFluzone HD+NuvaxovidIndicationFlu+COVID-19Flu+COVID-19Therapeutic AreaVaccines123RNameSP0291Phase123RDescriptionmRNA vaccineIndicationRSV+hMPV+PIV3 (older adults)RSV+hMPV+PIV3 (older adults)Therapeutic AreaVaccines123RNameSP0340Phase123RDescriptionSubunit vaccineIndicationRSV+hMPV (older adults)RSV+hMPV (older adults)Therapeutic AreaVaccines123RNameSP0341Phase123RDescriptionSubunit vaccineIndicationRSV+hMPV+PIV3 (older adults)RSV+hMPV+PIV3 (older adults)Therapeutic AreaVaccines123RNameSP0342Phase123RDescriptionSubunit adjuvanted vaccineNewIndicationShinglesNewShinglesNewTherapeutic AreaVaccines123RNameSP0256Phase123RDescriptionmRNA vaccineIndicationRSV+hMPV (older adults)RSV+hMPV (older adults)Therapeutic AreaVaccines123RNameSP0268Phase123RDescriptionmRNA vaccineIndication Acne AcneTherapeutic AreaVaccines123RNameSP0289Phase123RDescriptionmRNA vaccineIndicationFlu H5 pandemicFlu H5 pandemicTherapeutic AreaVaccines123RNameSP0335Phase123RDescriptionInactivated adjuvanted vaccineIndicationFlu H5 pandemic Flu H5 pandemic Therapeutic AreaVaccines123RNameSP0087Phase123RDescriptionVero cell vaccineIndicationRabiesRabiesTherapeutic AreaVaccines123RNameSP0202Phase123RDescription21-valent conjugate vaccineIndicationPneumococcal disease (children)Pneumococcal disease (children)Therapeutic AreaVaccines123RNameSP0218Phase123RDescriptionVero cell vaccineIndicationYellow feverYellow feverTherapeutic AreaVaccines123RNameFluzone HDPhase123RDescriptionMultivalent inactivated vaccineIndicationFlu (50 years+) (US, EU)Flu (50 years+) (US, EU)
[H2] Downloads Available
Full PipelineRich Pipeline NewsflowPipeline Progress
[H2] Related Links
[IMG: Shuang Yang, with dark tied up hair and safety glasses, as seen through some equipment in a lab, with only her head visible]
[H3] Research & Development
See more
[IMG: An overhead view of a technician weighing a large plastic container of white powder, with hundreds of smaller containers nearby]
[H3] Technology Platforms
See more
[IMG: Overhead view of a desk with a healthcare professional and a patient in conversation, stethoscope and laptop visible.]
[H3] Clinical Trials & Results
See more

[H1] Stories
We go beyond science and manufacturing to turn the impossible into possible.
Read our latest stories to follow what we are doing today to make a better tomorrow for people around the world.
[H2] In the Spotlight
[IMG: The F protein of the Respiratory Syncytial Virus (RSV), with a molecular clamp (purple) and key epitopes exposed (yellow).]
Our ScienceApril 20, 2026
[H5] Shape Matters: Inside Molecular Clamp Vaccines
Most people don't think about how a vaccine is designed. They think about the appointment, the needle, maybe a sore arm later that day. But behind the scenes, scientists are working through a surprisingly delicate question: to design a more effective vaccine, how do you show the immune system what a virus really looks like?Read the article
[IMG: Mark, who lives with severe hemophilia A, with his family.]
Your HealthApril 17, 2026
[H5] It’s Time to Look Beyond the Bleed
Read the article
[IMG: 3D molecular model of a NANOBODY® molecule showing purple and gray spheres connected by bonds against a gradient background]
Our ScienceJanuary 26, 2026
[H5] Two’s Company. Three’s a Crowd. Five Nanobody® Subunits? That Could Be a New Medicine.
Read the article
[H2] Watch Our Latest Videos
[IMG: Smiling woman in a modern office environment.]
[H3] AI in Manufacturing & Supply
[IMG: Brandon, an AI expert specializing in clinical trials, seated at a desk in a modern office with exposed brick walls and a large window providing natural light.]
[H3] How is AI Speeding up Drug Discovery?
[H3] Is AI a Superpower?
[H3] The Sanofi Connection
[H2] All Stories
YearTopicYour HealthApril 27, 2026
[H3] Global Hemophilia Survey Amplifies Patient and Caregiver Voices
Read the articleOur ScienceApril 20, 2026
[H3] Shape Matters: Inside Molecular Clamp Vaccines
Read the articleYour HealthApril 17, 2026
[H3] It’s Time to Look Beyond the Bleed
Read the articleOur ScienceApril 3, 2026
[H3] The Fast (And Intense) Lane: How Expedited Approvals Are Going Further and Faster for Patients
Read the articleOur ScienceMarch 30, 2026
[H3] Making it Real: Turning New Scientific Breakthroughs into Reality for Patients
Read the articleSustainabilityMarch 26, 2026
[H3] Inside Healthcare’s Trust Gap: Insights from Across the Globe
Read the articleYour HealthMarch 9, 2026
[H3] More Than Multiple Myeloma; Understanding the Unseen Burdens
Read the articleAI in HealthcareFebruary 24, 2026
[H3] AI Across the R&D Value Chain: Portfolio Decision-Making
Read the articleSustainabilityFebruary 19, 2026
[H3] Strengthening Djibouti’s Fight Against Non Communicable Diseases
Read the article

Marcy, FranceMarcy, France
[H1] Our Strategy
We’re on a mission to go further, faster for patients. To take the lead through breakthrough science and by striving to be a driver of progress and positive impact for the people and communities we serve.​
[H2] The Voices Behind Our Purpose
We chase the miracles of science to improve people’s lives, and sometimes that means starting over with Plan B, Plan C, or even Plan Z.  This film brings together the inner thoughts and ambitions of the people at Sanofi, who find inspiration from loved ones, motivation from families, and a united strength to push harder until we turn a corner.
Abhishek Shettar, mRNA - Scientist DP-LNP formulation Development, US
[H2] Further, Faster for Patients
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth.
We apply our deep understanding of the immune system to invent medicines and vaccines that positively impact millions of patients suffering from dermatological, respiratory, gastroenterological, and other immune-mediated diseases. And we are pioneering an innovative pipeline that could benefit millions more.
We’re on a mission to go further, faster for patients. To take the lead through breakthrough science and by leveraging our broad set of technology and manufacturing platforms, including mRNA.
See moreElsa Diffo Tiayo, Contigent Worker, US
[H2] Advancing Breakthrough Science
We’re strengthening our pipeline with a steady stream of potentially transformative therapies that could shift paradigms in treatment and prevention for people across the world.
We have a powerful toolbox of drug discovery platforms that allow us to break scientific ground in six therapeutic areas: Immunology and Inflammation, Oncology, Rare Diseases, Rare Blood Disorders, Neurology and Vaccines.
See moreLandscape around Garrarus beach, Waterford, Ireland
[H2] Advancing Sustainability
Peoples’ health and the environment are inextricably linked. 3.6 billion people live in areas sensitive to environmental issues that exacerbate disease  in strained healthcare systems.
Our ambition is to tackle the impact of environmental challenges on health and health care.  We do this by focusing on three dimensions: improving equitable and sustainable access to healthcare, reducing the environmental impact of our activities, and helping transform the delivery of care to minimize the environmental footprint of healthcare systems. Further, we work actively to embed sustainability in everything we do across the business.
See moreMireia Pages and Julia Fernandez, Sanofians
[H2] Going “All in” for Inclusion
Inclusion is everyone’s business. We integrate inclusion across every aspect of our business—from strategy to delivery—creating an inclusive culture that drives breakthrough science for patients.
Across every stage of our journey – from research and development to manufacturing and delivery – our inclusive culture shapes how we innovate, collaborate and deliver breakthrough science that responds to patients’ realities.
See more
[H2] How We’re Progressing
[H3] Q1 2025 Quarterly Financial Results
Discover more
[H3] Our ESG Commitment
See more
[H3] Our Form 20-F
Download PDF
[H2] Explore More
[H3] Investor Relations
See more
[H3] Code of Conduct
Explore site
[H2] Pursue Progress. Discover Extraordinary.
Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.
Explore Career Opportunities

Landscape around Garrarus beach, Waterford, IrelandLandscape around Garrarus beach, Waterford, Ireland
[H1] Sustainability
We are at the forefront of addressing some of the world's most critical challenges, striving to create a healthier, more resilient future. We are harnessing our expertise and innovative thinking to focus on the vital link between environmental challenges and human health. The time to act is now.The impact of environmental change is widespread, harming our health, the planet and the resilience of healthcare systems. Building on our strengths and business strategy, we are well-positioned to tackle the impact of environmental changes on health and health care. We also strive to embed sustainability across all aspects of our business.
[IMG: Audrey Duval]
Audrey DuvalExecutive Vice President, Corporate Affairs, President Sanofi France
[H2] Bridging Environment and Health for a Better Future
Environmental challenges are intensifying, reshaping our world, exacerbating certain diseases and worsening inequities in healthcare and access to quality medicines, with vulnerable communities being disproportionately affected.
We are committed to taking concrete actions to address the impact of environmental challenges on health and healthcare. By focusing on this intersection, we are uniting our sustainability efforts with a renewed focus on key areas for maximum impact:  building on our longstanding efforts towards sustainable and equitable access to healthcare, reducing the environmental impact of our products and activities across the value chain, and helping to transform the delivery of care to support the resilience of healthcare systems. Our goal is to build a healthier and more resilient world, for patients, the planet and society.
[H2] Our Achievements
Our initiatives in sustainability so far have delivered measurable results and enable us to bring experience and innovative thinking to our refocused approach.
[H3] >790,000
Non-communicable disease patients reached through our Global Health Unit
[H3] -47%
Reduction in GHG emissions in 2024 vs 2019 (scopes 1&2)
[H3] 46%
of senior leadership roles and 43% of executive roles are held by women
[H3] #7
Ranked Sustainable Company by Time Magazine1 (in 2024)
[H3] #3
Ranking on Access to Medicine Index2 (up from #8 in 2022)
Dr Ariany Widiastuty gives some advice for Syamsina daughter at Penyengat Olak public health centre, Jambi, Indonesia
[H2] Sustainable and Equitable Access to Healthcare
We are focused on improving and accelerating sustainable and equitable access to our medicines, vaccines and related care for underserved communities across  high-impact geographies. We are building comprehensive access to care programs particularly to tackle diseases worsened by environmental challenges for sustainable impact.
Learn moreFocus on an analysis carried out by the quality control department, Goa, India
[H2] Environmental Impact
We’re reducing the environmental impact of our products and activities across the value chain while adapting our business to environmental challenges (climate- and nature-related), around the world.
Learn moreDr. Yohana Mokiwa speaking with a patient in a pop-up clinic, Dar es Salaam, Tanzania
[H2] Healthcare Systems’ Resilience
We’re contributing to the delivery of care transformation through collective efforts that reduce healthcare systems’ environmental footprints and improve their resilience. That means using data to support decarbonization of the health care pathway in ways that also better address patients’ needs.
Learn more
[H2] Discover More
[H3] Global Health Unit
Our pioneering not-for -profit unit provides access to Sanofi quality medicines, with a focus on non-communicable diseases, in 40 countries with the greatest unmet medical needs while funding local support programs.
Learn more
[H3] Inclusion
Across every stage of our journey – from research and development to manufacturing and delivery – our inclusive culture shapes how we innovate, collaborate and deliver breakthrough science that responds to patients’ realities.
Learn more
[H3] Environment, Social, Governance
We communicate transparently on our ESG Performance on a regular basis.
Learn more
[H3] Responsible Business
As a global organization, we strive to conduct our business in a responsible and sustainable way.
Learn more
[H2] Recent News
[H3] Enhancing Our R&D Strategy: Integrating Environmental Impact for Sustainable Innovation and Resilience
Read the article
[H3] The Link Between Climate and Health: We Chart a New Course
Read the article
[H3] Data-Driven Solutions and Shared Responsibility to Address Global Health Challenges
A new white paper developed with IQVIA outlines how we’re addressing global health challenges and prioritizing actions through systematic data-driven approach and partnerships.
Read more
[H2] References
"World's Most Sustainable Companies 2024," TIME, accessed March 21, 2025, https://time.com/collection/worlds-most-sustainable-companies-2024/.
2024 Access to Medicine Index," Access to Medicine Foundation, accessed March 21, 2025, https://accesstomedicinefoundation.org/sectors-and-research/index-ranking.